ImmunityBio, Inc.
IBRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable. The $8.56B market capitalization puts IBRX squarely in mid-cap range for its industry. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Market Cap
$8.56B
Beta
0.14
P/E (TTM)
—
P/E (Fwd)
-63.79
EPS (TTM)
$-0.95
EPS (Fwd)
$-0.13
ROE
—
ROA
-30.5%
Cash
$357.4M
Total Debt
$1.23B
Free CF
-$186.6M
52W Change
214.4%
Annual Financials
Cash vs Debt
Where IBRX stands vs its 150-day and 200-day moving averages
As of the August 12, 2026 close, IBRX finished 2.84% above its 150-day moving average ($7.39) and 24.79% above its 200-day moving average ($6.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IBRX overbought or oversold?
At the August 12, 2026 close, IBRX's RSI(14) was 51.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, IBRX has $357.4M in cash with $1.23B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$186.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $240K (2022) to $113.3M (2025), reflecting a 47103% increase over the period.
With a beta below 0.7, ImmunityBio, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing IBRX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.